COVAPRIL TABLET 4MG

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

PERINDOPRIL ERBUMINE

Boleh didapati daripada:

DUOPHARMA (M) SDN. BHD.

INN (Nama Antarabangsa):

PERINDOPRIL ERBUMINE

Unit dalam pakej:

30Tablet Tablets; 100Tablet Tablets

Dikeluarkan oleh:

DUOPHARMA MANUFACTURING (BANGI) SDN BHD

Risalah maklumat

_Consumer Medication Information Leaflet (RIMUP) _
COVAPRIL TABLET®
Perindopril Erbumine 4mg
WHAT IS IN THE LEAFLET?
1.
What COVAPRIL is used for
2.
How COVAPRIL works
3.
Before you use COVAPRIL
4.
How to use COVAPRIL
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of
COVAPRIL
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of Revision
WHAT COVAPRIL IS USED FOR
This medicine is used to:
•
treat
high
blood
pressure
(hypertension)
•
treat heart failure (a condition
where the heart is
unable to
pump
enough
blood
to
meet
the body’s needs)
HOW COVAPRIL WORKS
COVAPRIL
tablet
belongs
to
a
group
of
medicines
called
ACE
Inhibitors.
These
group
of
medicines works by widening the
blood
vessels.
This
makes
it
easier
for
your
heart
to
pump
blood through the body.
BEFORE YOU USE COVAPRIL_ _
-
_When you must not use it _
•
if
you
are
allergic
(hypersensitive) to perindopril
or
to
any
of
the
other
ingredients
of
COVAPRIL
tablets
or
to
any
other
ACE
Inhibitor
•
if you have in the past suffered
from acute swelling of the face,
tongue
or
larynx
(angioneuriotic
syndrome),
regardless of whether or not it
has been caused by treatment
with
similar
medicine
(ACE
Inhibitor).
•
if you are more than 3 months
pregnant. It is also better to
avoid
COVAPRIL
tablets
in
early pregnancy.
Children: COVAPRIL tablets are
not for use in children.
-
_Before you start to use it _
If
you
experience
any
of
the
following, please tell your doctor
before
you
start
taking
COVAPRIL tablet:
•
if you have narrowing of the
heart valves (aortic or mitral
stenosis)
or
heart
muscle
disease
(hypertrophic
cardiomyopathy) or narrowing
of
the
artery
supplying
the
kidney with blood (renal artery
stenosis)
•
if
you
have
recently
had
a
kidney transplant
•
if you have any other heart or
liver or kidney problems, or if
you are having dialysis
•
if you have diabetes which is
not well controlled
•
if you have been told the limit
the salt in your diet or to use a
salt-substitute
containing
potassium
•
i

Ciri produk

COVAPRIL TABLET 4MG
[DUOPHARMA (M) SDN BHD]
DESCRIPTION:
An oblong, scored, white to off-white tablet.
COMPOSITION:
Each tablet contains: Perindopril Erbumine 4mg.
PHARMACODYNAMICS:
Perindopril following hydrolysis to perindoprilat, inhibits
angiotensin converting enzyme (ACE) both in vitro and in vivo. It is
thought that ACE inhibitors reduce blood pressure by inhibiting the
enzyme which
catalyses the conversion of angiotensin I to angiotensin II. Decreased
plasma angiotensin II leads to increased plasma renin activity and a
decrease in aldosterone. In addition to its effects on circulating
ACE, Perindopril binds to,
and inhibits tissue converting enzyme, predominantly in the kidney and
vascular wall. The contribution of this mechanism to the overall
antihypertensive effect of Perindopril is unknown. Perindopril may
also inhibit the
degradation of
the potent vasodepressor peptide, bradykinin, and this action may
contribute to its antihypertensive action. Perindopril appears to
reduce peripheral resistance and may influence arterial compliance.
The administration of
Perindopril to patients with essential hypertension results in a
reduction in supine and standing blood pressure without any
significant effect on heart rate. Abrupt withdrawal of Perindopril has
not been
associated with a
rebound rise in blood pressure.
PHARMACOKINETICS:
Following oral administration, Perindopril is rapidly absorbed and is
61-85% bioavailable. Elimination is rapid, occurring predominantly via
the urine. Plasma t 1/2 = 1 hour. Biotransformation of perindopril to
the active metabolite perindoprilat is approximately 20%. Peak plasma
concentrations of perindoprilat occur 3 to 4 hours after oral
administration of Perindopril and peak pharmacological activity occurs
after 4 to 6 hours. Protein
binding of perindoprilat is below 30%. Perindoprilat binds to plasma
and tissue ACE, and free perindoprilat is eliminated through the
urine. The elimination half life of the free fraction is between 3 and
5 hours. The terminal half life,
which corres